Eli Lilly's $3.2B Morphic Deal Is 'Crucial,' Has 'Strategic Merit' Despite Investor Attention On Obesity: Analyst
Eli Lilly's $3.2B Morphic Deal Is 'Crucial,' Has 'Strategic Merit' Despite Investor Attention On Obesity: Analyst
Eli Lilly And Co (NYSE:LLY) agreed to acquire Morphic Holding Inc (NASDAQ:MORF) for $57 per share in cash, an aggregate of approximately $3.2 billion.
禮來買下Morphic Holding Inc的股票，每股價格爲57美元，總額約爲32億美元。
Lead asset MORF-057 is a small-molecule inhibitor that is currently in Phase 2b trial for ulcerative colitis, with a readout expected in the first half of 2025. It recently initiated a Phase 2 study in Crohn's disease.
主導資產MORF-057是一種小分子抑制劑，目前正在進行第二期臨床試驗，用於治療潰瘍性結腸炎，預計於2025年上半年讀出結果。最近開始了Crohn's病的第二期研究。
Also Read: Eli Lilly's Alzheimer's Therapy's Broad Label Reflects Regulatory Confidence in Anti-Amyloid Antibodies: Analyst.
還閱讀：愛力治療阿爾茨海默氏病的廣泛標籤反映了監管機構對抗β澱粉樣抗體的信心：分析師。
Goldman Sachs writes that α4β7 is a clinically validated target in inflammatory bowel disease (IBD), as it notes Takeda Pharmaceutical Company Ltd's (NYSE:TAK) Entyvio generated $5.3 billion sales fiscal year 2023 in UC and Crohn's disease.
高盛稱α4β7是炎症性腸病（IBD）中一種經過臨床驗證的靶點，因爲它指出武田製藥股份有限公司的Entyvio在潰瘍性結腸炎和Crohn病中在2023財年實現53億收入。
The analyst notes the proposed deal has strategic merit and would present a potentially helpful step toward strengthening the company's pipeline portfolio in Immunology.
分析師指出，該提議交易具有戰略意義，並將成爲加強公司免疫學管道組合的潛在有益步驟。
Although investors are primarily focused on the obesity franchise's performance and outlook, deals like these are crucial for strengthening the company's diverse therapeutic areas, such as Immunology.
儘管投資者主要關注肥胖治療領域的業績和前景，但是像這樣的交易對於加強公司的免疫學等其他治療領域至關重要。
Despite receiving less attention from investors, Immunology remains an important development area for the company.
儘管投資者沒有給予充分的關注，但免疫學對於公司的發展仍然是一個重要的領域。
Last year, Eli Lilly acquired DICE Therapeutics, a biopharmaceutical company that leverages its proprietary DELSCAPE technology platform to develop oral therapeutic candidates for immunology indications for $48 per share.
去年，伊利製藥以48美元/股收購生物製藥公司DICE Therapeutics，該公司利用其專有的DELSCAPE技術平台開發口服免疫學適應症的治療候選藥物。
Goldman Sachs reiterates the Neutral rating with a price target of $793.
高盛重申中立評級，給出793美元的目標價格。
Price Action: LLY shares are up 0.72% at $924.64 at last check Tuesday.
股價行情：LLY股價上漲0.72％，最新報924.64美元於週二最後一次檢查。
- Eli Lilly's Mounjaro Outpaces Novo Nordisk's Ozempic In Weight Loss Effectiveness, Study Shows.
- 研究表明，伊利製藥的Mounjaro減肥勝過諾和諾德的Ozempic。
譯文內容由第三人軟體翻譯。